Drug intelligence / Profile preview

BLVD301

Development stage: Preclinical
Lead developer: Boulevard Bio

Overview

BLVD301 is a pipeline drug candidate being developed by Boulevard Bio, a precision immunology company. It is directed at a novel target combination in B cell-driven autoimmune disease, supported by established genetic evidence. The company nominated BLVD301 as a development candidate in June 2026. As of August 2026, specific details regarding its active ingredient, biological targets, and modality remain undisclosed.

Beyond the preview

Go deeper on BLVD301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLVD301.

Explore the full profile